PolyPid Q3 net loss narrows 23% to $5.75 million
PYPD•PolyPid’s third-quarter 2026 net loss narrowed 23% year over year to $5.75 million, while research and development expenses rose 24% to $6.52 million. A post-quarter $15 million Azurity payment strengthened liquidity, and management expects cash and anticipated proceeds to fund operations into 2028.
1. Quarterly results and outlook
PolyPid’s third-quarter 2026 net loss narrowed 23% year over year to $5.75 million. Research and development expenses rose 24% to $6.52 million, which the company attributed to NDA-related activities and commercial readiness preparations. A $15 million payment from Azurity after the quarter strengthened liquidity; management expects cash and anticipated proceeds to fund operations into 2028. D-PLEX₁₀₀ has a November 28, 2026, FDA decision target, with a potential U.S. launch in early 2027, subject to approval.
